GLUEMonte Rosa Therapeutics, Inc.
$10.32+63% 1Y
$10.32
$6.3352 weeks$25.31
Is the price fair?
What GLUE's price assumes
Monte Rosa Therapeutics, Inc. did not earn a profit over the last twelve months, so it has no trailing P/E and the price is measured against sales instead: 14.8× revenue.
14.8
Price / sales · no P/E: the last twelve months did not end in a profit
- Price / book
- 7.85
Price / book · today's price, fiscal year to Dec 31, 2025
- EV / sales
- 13.8
EV / sales
Details›
- Price / booktoday's price, fiscal year to Dec 31, 2025
- 7.85
- EV / EBIToperating margin −633%: the multiple describes the denominator
- not meaningful
- EV / salestoday's price, fiscal year to Dec 31, 2025
- 13.8
- Market capitalisation
- $1.83B
Multiples from SEC filings and end-of-day closes; implied growth from a reverse discounted cash flow. Group medians across the names Ryufin tracks.
On our screens:Most shorted stocks